← Eichor
Study identifier: NCT01050504 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Condition: Localized Renal Pelvis and Ureter Urothelial Carcinoma · Malignant Solid Neoplasm · Metastatic Malignant Neoplasm in the Bone  ·  Sponsor: University of Washington

PhaseN/A
Planned participants1500
Who can joinMale, 18 Years to no upper limit
Healthy volunteersYes

About this study

This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder/urothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Robert B. Montgomery  ·  206-598-0856  ·  rbmontgo@uw.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT01050504